Saturday, June 3, 2023, Chicago, Illinois, 6:45 AM – 7:45 AM Central Time (7:45 AM – 8:45 AM Eastern Time)

Breakfast with the Investigators: Hepatobiliary Cancers

A CME Hybrid Symposium Held in Conjunction with the 2023 ASCO Annual Meeting

Location
Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Program Schedule — Central Time
6:15 AM – 6:45 AM — Registration and Breakfast
6:45 AM – 7:45 AM — Educational Meeting

Meeting Room
Grand Ballroom (Level 2)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.  
 
Faculty
Anthony El-Khoueiry, MD
Associate Professor of Medicine
Associate Director for Clinical Research
Phase I Program Director
USC Norris Comprehensive Cancer Center
Los Angeles, California

Robin K (Katie) Kelley, MD
Professor of Clinical Medicine, Division
of Hematology/Oncology
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco (UCSF)
San Francisco, California


Professor Arndt Vogel, MD
Managing Senior Consultant
Department of Gastroenterology, Hepatology
and Endocrinology
Hannover Medical School
Hannover, Germany



Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Eisai Inc, Exelixis Inc, Incyte Corporation, Jazz Pharmaceuticals Inc, Merck, Seagen Inc, and Servier Pharmaceuticals LLC.
Program Schedule — Central Time
6:15 AM – 6:45 AM — Registration and Breakfast Buffet
6:45 AM – 7:45 AM — Educational Meeting

MODULE 1: First-Line Therapy for Advanced Hepatocellular Carcinoma (HCC) and Biliary Tract Cancers (BTCs)

  • Recently presented results from the Phase III IMbrave050 study investigating atezolizumab/bevacizumab for patients with HCC at high risk of recurrence after surgical resection or ablation
  • Clinical and biologic factors affecting the selection of up-front therapy for patients with advanced HCC
  • Long-term findings from the Phase III IMbrave150 trial comparing atezolizumab/bevacizumab to sorafenib as first-line therapy for unresectable HCC; optimal integration into routine practice
  • Efficacy and safety outcomes reported with durvalumab/tremelimumab for previously untreated advanced HCC in the Phase III HIMALAYA study; recent FDA approval and current clinical role of this combination
  • Mechanism of action of tislelizumab; similarities and differences with commercially available anti-PD-1/PD-L1 antibodies
  • Available results from the Phase III RATIONALE 301 trial comparing tislelizumab to sorafenib as first-line treatment for advanced unresectable HCC; potential clinical role
  • Current clinical utility of tyrosine kinase inhibitor (TKI) monotherapy as first-line treatment for unresectable HCC; available data demonstrating a potential advantage with lenvatinib compared to atezolizumab/bevacizumab for nonviral disease
  • Major efficacy and safety findings with the addition of durvalumab to first-line chemotherapy for advanced BTCs in the Phase III TOPAZ-1 trial; FDA approval of up-front durvalumab and implications for clinical practice
  • Recently presented results from the Phase III KEYNOTE-966 trial of pembrolizumab combined with cisplatin/gemcitabine compared to chemotherapy alone as first-line treatment for advanced BTCs; potential clinical role

MODULE 2: Selection and Sequencing of Therapy for Relapsed/Refractory (R/R) HCC

  • Factors in the selection and sequencing of treatment for patients with advanced HCC whose disease has progressed on first-line and consecutive lines of therapy
  • Role of multitargeted TKIs approved in the first-line setting, such as sorafenib and lenvatinib, for relapsed disease
  • Long-term outcomes with approved anti-angiogenic agents for progressive HCC, including regorafenib, cabozantinib and ramucirumab
  • Results from the Phase III KEYNOTE-394 trial and other pivotal studies examining the role of single-agent immune checkpoint inhibitors for R/R HCC
  • Key findings with anti-PD-1/PD-L1 and anti-CTLA-4 combination regimens for progressive HCC
  • Ongoing studies evaluating immune checkpoint inhibitor-based strategies for patients with HCC who have experienced disease progression on first-line atezolizumab/bevacizumab
  • Other promising agents and strategies currently under investigation for HCC

MODULE 3: Integration of Targeted Therapy into the Management of Advanced BTCs

  • Spectrum and frequency of molecular alterations in cholangiocarcinoma and other BTCs; optimal timing and type of genomic analysis to identify actionable abnormalities
  • Principal efficacy and safety findings with pemigatinib and futibatinib for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or other rearrangements
  • Published outcomes from the Phase III ClarIDHy study of ivosidenib for previously treated advanced cholangiocarcinoma with an IDH1 mutation; optimal incorporation into clinical practice
  • Ongoing research evaluating targeted therapies, such as FGFR inhibitors or ivosidenib, for newly diagnosed cholangiocarcinoma
  • Emerging results from the pivotal Phase IIb HERIZON-BTC-01 trial investigating the novel HER2-targeted bispecific antibody zanidatamab for previously treated HER2-amplified and HER2-expressing BTCs
  • Published (eg, the Phase II HERB study) and emerging (eg, the Phase II DESTINY-PanTumor02 study) efficacy and safety outcomes with trastuzumab deruxtecan for HER2-expressing BTCs
  • Emerging efficacy and safety findings among patients with previously treated HER2-positive BTCs from the Phase II SGNTUC-019 basket study of tucatinib and trastuzumab
  • Other promising biomarker-based strategies for advanced BTCs

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hepatobiliary cancers.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Appreciate Phase III data leading to the FDA approvals of novel first-line treatment strategies for unresectable or metastatic hepatocellular carcinoma (HCC), and discuss how these approaches can be optimally integrated into the clinical care of patients.
  • Establish an evidence-based approach to the selection and sequencing of available therapeutic options for patients with progressive HCC.
  • Discuss the biological justification for the evaluation of immune checkpoint inhibitors for advanced biliary tract cancers, and develop strategies to optimally incorporate anti-PD-1/PD-L1 antibodies into patient care.
  • Recognize the molecular heterogeneity of cholangiocarcinoma and other biliary tract cancers, and appreciate the biological rationale for efforts to exploit documented abnormalities.
  • Assess key data sets supporting the recent FDA approvals of fibroblast growth factor receptor (FGFR) inhibitors for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement in order to optimally select and sequence these agents in the care of appropriately identified patients.
  • Develop an understanding of available clinical trial findings supporting the use of IDH1 inhibitors for advanced cholangiocarcinoma with an IDH1 mutation in order to determine the applicability of this strategy in current clinical practice.
  • Recall available and emerging data with investigational agents and strategies currently in clinical testing for hepatobiliary cancers, and appropriately refer eligible patients for trial participation.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr El-Khoueiry — Advisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis Inc, Genentech, a member of the Roche Group, Merck, Qurient, Senti Bio, Tallac Therapeutics; Contracted Research: Astex Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Auransa Inc, Fulgent. Dr Kelley — Advisory Committee (Payments to Institution): Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Merck; Consulting Agreements: Compass Therapeutics, Exact Sciences Corporation, Kinnate Biopharma, Regeneron Pharmaceuticals Inc, Tyra Biosciences; Contracted Research: Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, EMD Serono Inc, Exelixis Inc, Genentech, a member of the Roche Group, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Partner Therapeutics, QED Therapeutics, Relay Therapeutics, Surface Oncology, Taiho Oncology Inc; Data and Safety Monitoring Board/Committee (Uncompensated): Genentech, a member of the Roche Group, Merck; Travel Support: AstraZeneca Pharmaceuticals LP, Merck. Prof Vogel — Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Boehringer Mannheim, Bristol Myers Squibb, BTG, Daiichi Sankyo Inc, Eisai Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merck Sharp & Dohme LLC, Pierre Fabre, Roche Laboratories Inc, Servier Pharmaceuticals LLC, Sirtex Medical Ltd, Taiho Oncology Inc, Terumo Medical Corporation; Speaker: Advanced Accelerator Applications, Amgen Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Boehringer Mannheim, Bristol Myers Squibb, BTG, Daiichi Sankyo Inc, Eisai Inc, GSK, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jiangsu Hengrui Medicine Co Ltd, Merck Sharp & Dohme LLC, Pierre Fabre, Roche Laboratories Inc, Servier Pharmaceuticals LLC, Sirtex Medical Ltd, Taiho Oncology Inc, Terumo Medical Corporation.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Eisai Inc, Exelixis Inc, Incyte Corporation, Jazz Pharmaceuticals Inc, Merck, Seagen Inc, and Servier Pharmaceuticals LLC.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Grand Ballroom (Level 2)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

 
This activity is intended for medical and radiation oncologists, hematologists, hematology-oncology fellows, general and gastrointestinal surgeons and other healthcare providers involved in the treatment of hepatobiliary cancers.

​ ​ ​
IN-PERSON registration
Thank you for your interest in our CME program taking place in Chicago, IL. At this time online in-person preregistration is closed for this event. SEATS ARE STILL AVAILABLE FOR THE PROGRAM AND WILL BE OFFERED ON A FIRST COME FIRST SERVCE BASIS. Our Onsite Registration Desk will be open at 6:15 AM Central Time on Saturday, June 3. If you are interested in attending, please visit our registration desk located outside the Grand Ballroom (Level 2) of the Hilton Chicago hotel (720 South Michigan Avenue). ASCO offers complimentary shuttle service from the McCormick Place Convention Center to this hotel. Information on shuttle service is available on the 2023 ASCO Annual Meeting website. Please note: onsite registration does not guarantee meal service which will be based on availability.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

Registration for live webcast

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for Webcast »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

 

Not an official event of the 2023 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.